A U.S. cannabis company has approached Aurora Cannabis Inc., expressing interest in acquiring the Edmonton-based firm. Aurora has announced the establishment of a special committee to evaluate the unsolicited bid following the disclosure by Curaleaf Holdings Inc. of their intention to acquire all shares of the company.
Should the acquisition succeed, a merged entity would be formed with a presence in 17 countries spanning Europe, North America, and other global markets, according to Curaleaf. The Connecticut-based company, listed on the Toronto Stock Exchange, stated that it decided to make its bid public after unsuccessful attempts to engage in private negotiations with Aurora’s leadership.
Curaleaf reported that Aurora’s board declined to enter discussions after receiving a formal letter of intent from Curaleaf’s CEO on June 23. Despite a subsequent follow-up letter on July 7, Aurora allegedly did not engage in meaningful conversations. In response, Curaleaf expressed disappointment and declared their intention to directly engage Aurora shareholders due to the perceived value and strategic benefits of the transaction.
The proposed deal suggests offering Aurora shareholders $4 US per share, in addition to $0.75 US in cash for each Aurora share. Aurora acknowledged receiving communication from Curaleaf outlining acquisition proposals but disputed the claim that they rejected the offer. The Canadian company highlighted ongoing correspondence between their lead independent director and Curaleaf’s CEO.
Aurora plans to convene a special committee comprising independent directors to assess the proposal’s alignment with stakeholders’ interests. They stressed that the outcome is uncertain, and operations will continue normally during the evaluation process. Despite interest from Curaleaf, analysts expressed reservations about the offer’s valuation, emphasizing Aurora’s potential for long-term growth and value creation.
Curaleaf’s CEO emphasized the potential value creation through a merger, citing the combination of their global distribution network with Aurora’s strong international medical cannabis presence. The companies collectively generated over $1.5 billion US in revenue in the past year, with anticipated cost synergies exceeding $40 million US annually.
The proposed merger aims to offer Aurora shareholders an opportunity to participate in a diversified global platform and benefit from favorable U.S. regulatory trends, according to Curaleaf.